Navigation Links
InfoGroup Founder and Board Member Criticizes Adoption of Poison Pill
Date:5/18/2009

Board Should Pursue Strategic Alternatives Rather than Seek to Entrench Itself

OMAHA, Neb., May 18 /PRNewswire/ -- Vinod Gupta, the founder, member of the board of directors and holder of approximately 39% of the outstanding stock of InfoGroup (Nasdaq: IUSA) announced today that he strongly disagreed with the Company's recent decision to adopt a poison pill and believes that the Company must explore strategic alternatives.

"I believe that the Board of Directors' adoption of a 'poison pill' demonstrates that many of the directors are willing to entrench themselves at the expense of the Company's stockholders," said Mr. Gupta. "Unfortunately, this conduct is consistent with past Board actions. When I entered into a settlement agreement with the Company in 2008, the Board insisted that I vote all my shares in favor of the Board's nominees for director rather than proportionately with the shares of the Company's unaffiliated stockholders, as I had strongly demanded. The Board simply wanted to control my votes (approximately 39% of the Company's voting stock) to assure that they could keep their board seats rather than give the stockholders, to whom they should owe their allegiance, a meaningful say in the election of directors," Mr. Gupta stated.

"I regret that some members of this Board, who do not own a meaningful amount of stock in the Company like I do, seem much more interested in assuring that they retain their directorships than in doing what is best for the stockholders of the Company. I sincerely hope that all stockholders, as well as Risk Metrics, let these members of the Board know their displeasure with the Board's decision to adopt a rights plan," Mr. Gupta continued.

"It is bad enough that a majority of the Board would take this action against the best interests of all of the stockholders. However, in my case, their conduct amounts to a breach by the Board of an agreement between the Company and me, as described in the letter to the Board attached to this press release," said Mr. Gupta.

"Even the adoption of the poison pill might not be so bad in isolation. But the poison pill has to be judged against the background of the Company's dismal performance since new management was installed and other actions by a majority of the Board to feather the nest of directors and senior management. These include:

  • The Company's revenues in the March 2009 quarter declined 17% and operating income declined 34% from the first quarter of last year.
  • These results are much worse than the Company's peer group: in the March 2009 quarter, Dun & Bradstreet's revenues only declined 2% and its operating income actually increased 5% from the first quarter of last year.
  • The Board has discontinued the Company's annual dividend, depriving the stockholders of last year's dividend of $0.35 per share.
  • This dismal performance hasn't stopped the Board from treating itself and management quite well.
    • Four of the directors received directors fees of approximately $296,000, $288,000, $273,000 and $248,000, respectively, in 2008. This is a total of directors fees of approximately $1,105,000 for just these four directors.
    • The Board gave away more than 900,000 shares of restricted stock to senior management.
    • The Board gave change of control benefits for the four top officers that could total approximately $9,400,000.
    • The Board provided a compensation package to its new CEO, who has no experience in the industry, which contemplates $1,500,000 annual cash compensation as well as discretionary equity compensation. In 2008, the fair value of the CEO's discretionary equity compensation was $726,000, such that his total 2008 compensation was $2,226,000.

Mr. Gupta said.

"I strongly believe that it is in the best interests of the stockholders for the Board to explore the Company's strategic alternatives rather than for the Board to seek to entrench itself and waste money on the Board and the Company's top executives. In my capacity as a stockholder of the Company, I have been approached by both strategic and financial buyers about potential transactions but I believe the Company has failed to engage with them in any meaningful way. I remain open to a sale of the Company and would be willing to participate (or not participate) with the buyer if that helped get a transaction done," Mr. Gupta concluded.


'/>"/>
SOURCE Vinod Gupta
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
2. Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a Clean SCHIP Six-Month Extension
3. Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer
4. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
5. Susan G. Komen for the Cure Founder Sworn in as Chief of Protocol
6. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
7. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
8. Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show
9. Lenny Dykstra, Founder & President of The Players Club, to Keynote the 2008 Financial Communications Forum
10. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
11. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
Breaking Medicine Technology: